clinical trial · NCT07262476
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Minghui Pharmaceutical (Hangzhou) Ltd·phase3·recruiting·n = 258
Thyroid Eye Disease (TED)MHB018A injection
brief summary
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
started
Jan 9, 2026
primary completion
Jan 31, 2029
completion
Jan 31, 2030
last updated
Mar 30, 2026
detailed description
The primary objective of this study is to evaluate the improvement in proptosis from baseline (defined as the most recent measurement prior to the first dose in this study) following treatment with MHB018A Injection in subjects with active or chronic TED who previously received placebo in either the MHB018A-P-301 or MHB018A-P-302 studies, and the safety and tolerability of MHB018A Injection in TED subjects.
official title
A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol